<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03207724</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2016-07-Hendifar-OnFX</org_study_id>
    <nct_id>NCT03207724</nct_id>
  </id_info>
  <brief_title>Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia</brief_title>
  <acronym>OnFX</acronym>
  <official_title>A Phase I Study of Onivyde and 5-FU in Combination With Xilonix for Advanced Pancreatic Cancer With Cachexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Hendifar, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to examine the safety of the investigational drug, Xilonix(™),&#xD;
      in addition to standard doses of Onivyde® (nanoliposomal irinotecan) and 5- fluorouracil&#xD;
      (5FU)/folinic acid (leucovorin) for pancreatic cancer patients with cachexia. Cachexia is a&#xD;
      syndrome that includes involuntary weight loss and physical deterioration that can contribute&#xD;
      to poor outcomes of cancer treatment. In other studies, Xilonix has increased lean body mass&#xD;
      in advanced cancer patients. This increase could lead to improved weight maintenance and&#xD;
      quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will prospectively evaluate advanced pancreatic adenocarcinoma patients. The&#xD;
      intervention will be interleukin-1-alpha antagonist (Xilonix) in addition to standard&#xD;
      chemotherapy. The first aim is to assess the safety and identify the maximum tolerated dose&#xD;
      of Onivyde with 5-fluorouracil/folinic acid in combination with the study agent, Xilonix. The&#xD;
      study will also create a repository of serum, tissue, and fecal specimens to investigate&#xD;
      novel biomarkers related to cachexia with pancreatic adenocarcinoma and interleukin-1-alpha&#xD;
      blockade. Lastly, the study will assess for a correlation between cachexia, activity, and&#xD;
      PROs on domains of quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Actual">October 27, 2020</completion_date>
  <primary_completion_date type="Actual">November 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the determination of the Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 days (first cycle)</time_frame>
    <description>Assess safety of novel combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of onivyde, 5-fluorouracil/folinic acid in combination with Xilonix</measure>
    <time_frame>28 days (first cycle)</time_frame>
    <description>Assess MTD of Onivyde in combination with novel therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight stability</measure>
    <time_frame>6 months</time_frame>
    <description>Mean change from baseline (kg) up to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean Body Mass</measure>
    <time_frame>6 months</time_frame>
    <description>Mean change from baseline (kg) up to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
    <description>To measure overall survival up to 12 months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 months</time_frame>
    <description>To measure progression free survival up to 12 months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in global quality of life (QOL) score (EORTC Pan26)</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment based on patient-reported QOL up to 6 months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in global score of patient-reported response to therapy (FAACT questionnaire- Functional Assessment of Anorexia/Cachexia Therapy)</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment based on patient-reported outcomes up to 6 months from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Cachexia</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Xilonix plus Onivyde and 5FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>interleukin-1-alpha antagonist (Xilonix) in addition to standard chemotherapy of onivyde and 5-fluorouracil/folinic acid (leucovorin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xilonix plus Onivyde and 5FU</intervention_name>
    <description>Xilonix by IV</description>
    <arm_group_label>Xilonix plus Onivyde and 5FU</arm_group_label>
    <other_name>interleukin-1-alpha antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced or locally advanced pancreatic cancer patients (can include new or recurrent&#xD;
             diagnosis) referred to SOCCI-CSMC for chemotherapy that has progressed through or&#xD;
             intolerant to gemcitabine based chemotherapy&#xD;
&#xD;
          -  Cachexia defined as greater than 5% unexplained weight loss within any 6 month period&#xD;
             prior to screening visit OR as documented by the medical physician based on standard&#xD;
             diagnosis of cachexia&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  ECOG performance status 0-2 or Karnofsky PS &gt;60%&#xD;
&#xD;
          -  Patients must have normal organ and marrow function&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent&#xD;
&#xD;
          -  Negative pregnancy test for WOCBP&#xD;
&#xD;
          -  WOCBP and men must agree to use of adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are currently receiving any other investigational agents&#xD;
&#xD;
          -  Patients who have received more than one chemotherapeutic regimen in metastatic&#xD;
             setting&#xD;
&#xD;
          -  Patients with CNS metastases&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Patients with unresolved grade 3/4 adverse effects of prior therapy at time of&#xD;
             enrollment&#xD;
&#xD;
          -  Subjects with history of hypersensitivity to compounds of similar chemical or biologic&#xD;
             composition to Xilonix or Onivyde&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit the understanding or rendering&#xD;
             of informed consent&#xD;
&#xD;
          -  Patients with known Dihydropyrimidine dehydrogenase deficiency (DPD deficiency)&#xD;
&#xD;
          -  Patients known to be UGT1A1*28 allele homozygous&#xD;
&#xD;
          -  Patients who have had a live vaccine within 3 months of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Hendifar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Andrew Hendifar, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>advanced pancreatic cancer</keyword>
  <keyword>locally advanced pancreatic cancer</keyword>
  <keyword>recurrent diagnosis</keyword>
  <keyword>new diagnosis</keyword>
  <keyword>adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

